Topic: shareholder activism
Starboard Value is “certainly interested in the story at Bristol-Myers,” according to its leader. But that doesn’t mean it’s getting involved.
Unhappy with Allergan's performance and outlook, hedge fund Appaloosa once again called on the company to split up its CEO and chairman jobs.
Analysts and investors have both expressed concerns over Bristol-Myers Squibb’s $74 billion Celgene deal. And an activist may be joining that list.
A Bernstein analyst has previously said that breaking up crop and pharma would be the "best strategy" for Bayer.
Citing high risks, Kunio Takeda, the drugmaker's leader from 1993 to 2009, said he doesn't support the Shire acquisition.
A senior member of the founding Takeda family spoke out against the Shire deal for the first time, calling it a betrayal of company culture.
More turnover is coming to Allergan’s board—and this time, it’s the man who arguably built the company.
Ironwood may have avoided sparring with activists by introducing an R&D split-off, but its employees paid the price.
Allergan is in the middle of making some moves to revive its struggling shares. And the success of its pipeline could dictate its next moves, analysts say.
FDA clears Sun Pharma's key Halol plant, Eisai builds a new drug discovery center for Alzheimer's, opposition to the Takeda-Shire deal gains support.